BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32575541)

  • 1. Discovery of Isoplumbagin as a Novel NQO1 Substrate and Anti-Cancer Quinone.
    Tsao YC; Chang YJ; Wang CH; Chen L
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NADPH: Quinone oxidoreductase 1 (NQO1) mediated anti-cancer effects of plumbagin in endocrine resistant MCF7 breast cancer cells.
    Pradubyat N; Sakunrangsit N; Mutirangura A; Ketchart W
    Phytomedicine; 2020 Jan; 66():153133. PubMed ID: 31790893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Axis between the Long Non-Coding RNA
    Nakashima C; Fujiwara-Tani R; Mori S; Kishi S; Ohmori H; Fujii K; Mori T; Miyagawa Y; Yamamoto K; Kirita T; Luo Y; Kuniyasu H
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
    Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
    J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of 3-(1-benzotriazole)-nor-β-lapachones as NQO1-directed antitumor agents.
    Wu LQ; Ma X; Liu ZP
    Bioorg Chem; 2021 Aug; 113():104995. PubMed ID: 34034133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
    Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
    Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational designed highly sensitive NQO1-activated near-infrared fluorescent probe combined with NQO1 substrates in vivo: An innovative strategy for NQO1-overexpressing cancer theranostics.
    Gong Q; Yang F; Hu J; Li T; Wang P; Li X; Zhang X
    Eur J Med Chem; 2021 Nov; 224():113707. PubMed ID: 34303080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone.
    Pidugu LS; Mbimba JC; Ahmad M; Pozharski E; Sausville EA; Emadi A; Toth EA
    BMC Struct Biol; 2016 Jan; 16():1. PubMed ID: 26822308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
    Li X; Bian J; Wang N; Qian X; Gu J; Mu T; Fan J; Yang X; Li S; Yang T; Sun H; You Q; Zhang X
    Bioorg Med Chem; 2016 Mar; 24(5):1006-13. PubMed ID: 26803578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
    Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
    J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis.
    Wu Y; Wang X; Chang S; Lu W; Liu M; Pang X
    J Pharmacol Exp Ther; 2016 Jun; 357(3):466-75. PubMed ID: 27048660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
    Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
    Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
    Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
    Dehn DL; Winski SL; Ross D
    Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
    Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
    J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs.
    Phillips RM; Jaffar M; Maitland DJ; Loadman PM; Shnyder SD; Steans G; Cooper PA; Race A; Patterson AV; Stratford IJ
    Biochem Pharmacol; 2004 Dec; 68(11):2107-16. PubMed ID: 15498501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.
    Yan X; Su H
    Med Sci Monit; 2017 Apr; 23():1963-1972. PubMed ID: 28435150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
    Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
    Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
    Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
    J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
    Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
    J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.